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Abstract
Antibody-drug conjugates  (ADCs)  have emerged as  a  promising class  of  targeted
anticancer  therapy,  and  it  is  distinguished  from  traditional  chemotherapeutic  ap‐
proaches  by its  potential  to  kill  cancer  cells  with  limited side  effects.  Site-specific
conjugation is one of the current challenges in ADC development because it allows for
controlled conjugation and production of homogeneous ADCs. This chapter describes a
computational method for the generation of antibody-drug conjugates as PDB files
through site-specific cysteine conjugation, given the PDB files of a drug, a linker, and an
antibody. The drug and linker are reconfigured using the rotation and translation functions
of an affine transformation, which is brought in appropriate positions for the bonds to
occur between the three molecules. The hydrogen and disulfide bonds are employed to
connect the linker and drug as well as the linker with the antibody, respectively. Examples
of conjugates produced with the presented method have been demonstrated.
Keywords: bioinformatics, cancer, targeted therapy, antibody-drug conjugates, cys‐
teines
1. Introduction
Antibodies are large proteins produced by the immune system against an invader substance
called antigen. As proteins, they consist of one or more chains of amino acid residues, two types
of which are cysteines and lysines. Antibodies can also be manufactured and used as stand‐
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alone therapeutic agents for a number of diseases including cancer. The largest part of the amino
acid sequence of an antibody is conserved in all antibodies, with the exception of a small part
that is called a hypervariable (HV) region. Due to the specialized and unique amino acid sequence
of the HV region, an antibody has the ability to recognize and bind a specific antigen with higher
affinity than different antigens—a property called specificity. The specificity and long half-
lives of antibodies are valuable features to their therapeutic effect. However, the performance
of manufactured antibodies as standalone therapeutic agents is impeded by their limited
potency. On the contrary, traditional chemotherapeutic drugs are more potent but have short
half-lives and no specificity, targeting all cells indiscriminately. A class of targeted anticancer
therapy (TAT), that utilizes the best qualities of antibodies and cytotoxins by combining them
in one molecule, is antibody-drug conjugates (ADCs). ADCs are therapeutic agents formed by
three elements: an antibody whose target is a cancer-specific molecule, a cytotoxic agent, also
called the drug, and a linker molecule that connects them. An ADC ideally delivers the conjugated
cytotoxic molecule directly into cancer cells, limiting damage to healthy tissues [1–8].
The typical route of an ADC molecule upon its insertion to the bloodstream can be described
briefly with the following steps. At first, the ADC circulates in the plasma remaining stable,
while the drug remains inactive. When the target antigen is encountered, the antibody binds
to it. Typically, the ADC-antigen complex undergoes antigen-mediated or antigen-independ‐
ent internalization by the cancer cell. Subsequently, the ADC is degraded in its parts through
a process that depends on the type of linker used. ADCs containing a non-cleavable linker
usually undergo lysosomal digestion. The antibody is degraded to its amino acids and the final
active drug complex is the drug with the linker and a single amino acid. On the other hand,
the ADCs, containing a cleavable linker, are usually degraded through hydrolysis or enzymatic
cleavage. At that stage, the drug is activated and kills the cell, in a way that depends on the
type of the cytotoxic agent used. For example, auristatins and maytansinoids disrupt the
microtubule assembly of the cell, while calicheamicins and duocarmycins target its DNA
structure. An alternative ADC strategy is targeting the endothelial cells of the tumor vessels
in order to deprive the cancer cells from blood [6, 9–12].
Conjugation usually occurs at solvent-accessible reactive amino acids of the preserved regions
of the antibody, leaving the hypervariable regions of the antibody available for antigen
binding. The reactive thiol groups of cysteine residues, being made available for conjugation
after the reduction of the inter-chain disulfide bonds, as well as the amino groups of lysine
residues, are typical conjugation sites. However, these methods by default produce ADCs with
variable drug to antibody ratio (DAR) and conjugation sites, and therefore unstable pharma‐
cokinetic properties. For example, in cysteine conjugation, ADCs with a DAR of eight have a
significantly shorter circulation time compared to the unconjugated antibodies. On the other
hand, ADCs with a DAR of four have a longer circulation time than ADCs with the double
DAR, but the same therapeutic effect as them. More homogeneous ADCs can be produced by
site-specific conjugation methods, one of which is cysteine engineering. THIOMABs are
engineered antibodies in which cysteines have been introduced to the amino acid sequence by
substituting original residues. The ideal sites for residue substitution can be identified with
phage display techniques. Eight residues on the light chain (LC-V205C, LC-S168C, LC-A153C,
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LC-S127C, LC-S121C, LC-S114C, LC-V110C, LC-V15C) and five residues on the heavy chain
(HC-T116C, HC-S115C, HC-A114C, HC-S113C, HC-S112C) have been investigated as potential
cysteine insertion sites (Kabat numbering). The above amino acids were substituted with
cysteines, generating THIOMABs, which were subsequently conjugated with biotin-malei‐
mide. Considering the conjugation of two molecules per antibody as 100% conjugation
efficiency, most THIOMABs demonstrated more than 90% conjugation efficiency, proving to
be suitable for site-specific conjugation of thiol reactive probes. THIOMAB-drug conjugates
(TDCs) are the product of the conjugation of a drug to a THIOMAB [11, 13–28].
The process of drug discovery and development is rather strenuous, taking up to 15 years to
produce a new drug from the early in vitro discovery stages to the time it is available as a
treatment option. However, drug discovery can be facilitated by bioinformatic techniques. The
three-dimensional structure of a molecule can be described computationally in various
formats, a prevalent one being the Protein Data Bank (PDB) format [29–31]. Computational
drug design and molecular mechanics methods provide a means to model molecules and
assess their features. Even though there is a variety of general computer-aided drug design
tools, the more specific field of ADC computational design is less evolved. JSDraw–Antibody-
Drug Conjugates is an editor tool that can be used for ADCs, although it is drawing-oriented
and uses 2D coordinates. In addition, a mathematical model was recently developed to
describe mechanistically the pharmacokinetic behavior and preclinical efficacy of THIOMAB-
drug conjugates [32–41].
An attempt to contribute to the study of ADC computational modeling was made in [42]
describing the computational construction of ADCs through lysine conjugation. The three
input PDB files of the antibody, the linker, and the drug were processed and merged to a PDB
file that represented an ADC molecule. The linker and drug molecules were reconfigured and
aligned with the selected lysine amino acid, while hydrogen bonds linked the three molecules
[30, 31].
Figure 1. Scheme of the bonds formed between the drug, the linker, and the antibody molecules, according to the
method described in this paper.
The present chapter aims to extend the above-mentioned technique to a more site-specific
conjugation method, connecting the linker-drug complex to engineered cysteines instead of
lysines. The molecule C12S has been used as a non-cleavable linker. The linker and drug form
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a hydrogen bond (H bond), while the linker-drug complex and the engineered cysteine form
a disulfide bond (SS bond) (Figure 1). The configurational change of the linker and drug is
accomplished using the rotation and translation functions of an affine transformation.
Molecular modeling software was used for functions such as the visualization of molecules,
the addition of hydrogen atoms to the antibody PDB files, the insertion of cysteine amino acids
to the antibody sequence, as well as the generation of the linker PDB file.
2. Methods
The main aspects of the cysteine conjugation method have been analyzed here. Firstly, the
steps of the method are presented in detail. The Affine Transformation subsection contains the
definition of the affine transformation, as well as details concerning its application to this
project. The Rotation and Translation subsections focus on the application of the rotation and
translation functions to the reconfiguration of the molecules. The Axes and Distances subsec‐
tions contain the specifications made in relevance to the axes of the molecules involved and
the distances between them. Finally, the implementation of the method is described.
2.1. Method steps
First, the antibody, the cytotoxic agent, and the linker that will form the conjugate are deter‐
mined (step S1). The antibody PDB files we have used were obtained from the RCSB database,
while the drug PDB files from the NCI database. The linker PDB file was created with the
molecular modeling software UCSF Chimera [36]. Given an antibody PDB file, it is possible to
produce the PDB file of an engineered antibody (THIOMAB) by replacing selected antibody
residues with cysteines using molecular modeling software (step S2). The antibody was
selected to have solvent-accessible residues not in the hypervariable region of the antibody,
that are suitable to be replaced with cysteines and to be conjugated. The drug was selected so
as to have at least one hydrogen (H) atom bonded covalently to an electronegative (EN) atom,
in order to be able to form a hydrogen bond with the linker (Figure 1). The linker molecule
was designed to be able to form a disulfide bond with a cysteine. For that purpose, a sulfur (S)
atom was included. Also, the linker was designed to be long enough to allow for the drug to
be linked to the cysteine without colliding with the nearby residues. For that purpose, 12 carbon
(C) atoms were incorporated following a linear, instead of circular, layout. Finally, the linker
should theoretically be able to release the drug from the antibody inside the cancer cell. For
the molecule C12S we used, there are three possible ways for that to happen. Breakage of the
hydrogen bond between the drug and linker could occur. Also, the disulfide bond between
the linker and drug could break due to disulfide exchange, a phenomenon associated with
cleavable linkers. In addition, lysosomal digestion of the antibody could occur, in case the
disulfide bond between the cysteine and the linker does not break, a phenomenon associated
with non-cleavable linkers. In that case, the final active drug complex would contain a single
residue (the cysteine connected to the linker), the linker, as well as the drug.
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Even though the PDB format has more than 40 types of PDB records, the three types of records
that are crucial for the representation of three-dimensional molecular structure include the
PDB ATOM records, which contain information about the atoms of standard amino acids and
nucleotides. The PDB HETATM records contain information about additional “non-standard”,
non-polymer chemical structures of the molecule, and the PDB CONECT records specify the
connectivity between the atoms of the molecule [29].
Figure 2. Flowchart of the cysteine conjugation method described in this paper. S1. Determine the three molecules (an‐
tibody, drug, linker) that will build the antibody-drug conjugate. S1a. Select the antibody PDB file from the RCSB data‐
base (e.g., ab.pdb) according to the criteria described in Section 2.1. S1b. Select the anticancer drug PDB file from the
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NCI database (e.g., drug.pdb). S1c. Determine the linker PDB file (e.g., linker.pdb). S2. Engineer the antibody (ab.pdb)
to create a THIOMAB (e.g., thiomab.pdb), using molecular modeling software. S2a. Select one (or more) native resi‐
due(s) of the antibody (ab.pdb) to be replaced by a cysteine residue. The residue should be solvent-accessible, on the
surface of the antibody, in order to be accessible to the linker-drug complex, as well as suitable for cysteine replace‐
ment and site-specific conjugation. S2b. Replace the selected residue(s) with a cysteine residue. S2c. Add hydrogen
atoms to the antibody, since the antibody PDB files from the RCSB database are provided without them. S2d. Save the
engineered antibody (THIOMAB) to a new file (thiomab.pdb). S3. Load the necessary PDB records from the PDB files
of the engineered antibody (thiomab.pdb), the linker (linker.pdb) and the drug (drug.pdb). Those include (i) the PDB
ATOM, HETATM, and CONECT records of the engineered antibody; (ii) the PDB HETATM and CONECT records of
the linker; (iii) the PDB HETATM and CONECT records of the drug (the drug and linker files do not contain PDB
ATOM records). S4. Prepare the reconfiguration of the drug. S4a. Calculate the axis of the drug as specified in Eqs. (16–
18). Briefly, the drug axis has been specified as the line connecting the drug atoms participating in the hydrogen bond
with the linker, which are a hydrogen (H) atom and the electronegative (EN) atom bonded covalently to it. S4b. Calcu‐
late the axis of the linker as specified in Eqs. (19–21). Briefly, the linker axis has been specified as the line connecting
the two most distant non-hydrogen (NH) atoms of the linker, since that line is quite representative of the shape of the
linker. Given the chemical formula of the linker used (C12S), those were always the sulfur (S) atom and its most distant
carbon (C) atom. S4c. Find the atoms that will define the distance between the drug and linker according to Eqs. (30–
32). Briefly, the distance between the drug and linker can be described as the distance between the atoms participating
in the hydrogen bond between the two molecules, which are a hydrogen drug atom and an electronegative linker
atom. S5. Reconfigure the drug. S5a. Obtain the coordinates of the drug atoms from the drug PDB HETATM records
(drug.pdb). S5b. Rotate the drug using the affine transformation (Eqs. (1–15)). Apply the affine transformation to the
drug for a = 1, Tx = Ty = Tz = 0 and the values of the variables rx, ry, rz in [−180°, +180°] that satisfy a specific condition, as
defined in Eq. (28). Briefly, the condition can be specified as the minimization of the absolute value of the angle be‐
tween the axes of the drug and linker. S5c. Update (optional) the PDB drug records with the modified coordinates
from step S5b. S5d. Translate the drug using the affine transformation (Eqs. (1–15)). Apply the affine transformation to
the drug for a = 1, rx = ry = rz = 0 and the values of the variables Tx, Ty, Tz in [−D, +D] that satisfy a specific condition,
defined in Eq. (36). Briefly, the condition can be specified as the minimization of the absolute value of the difference
between the distance of the two molecules (defined in step S4c) and the official length of the hydrogen bond. S5e. Up‐
date the PDB records of the drug with the modified coordinates. S5f. Save updated PDB drug records in a new PDB file
(e.g., drug_rt.pdb). S6. Merge the PDB files of the linker and the reconfigured drug to produce the PDB file of the link‐
er-drug complex. S6a. Renumber the sequence numbers of the PDB records of the reconfigured drug, since they will be
placed after the PDB records of the linker in step S6c. S6b. Form computationally a hydrogen bond between the drug
and linker by updating the PDB CONECT records of the drug and linker. S6c. Save the necessary data to a new file
that will represent the linker-drug complex (e.g., linkerdrug.pdb). Those data include the (i) PDB HETATM records of
the linker (linker.pdb; from step S1c); (ii) renumbered PDB HETATM records of the reconfigured drug (from step S6a);
(iii) updated PDB CONECT records of the linker and drug, including the one that represents the new hydrogen bond
(from step S6b). S6d. Load the records of the linker-drug complex (from step S6c) into appropriate structures, to use in
the steps S7–S9. S7. Prepare the reconfiguration of the linker-drug complex. S7a. Calculate the axis of the linker-drug
complex as specified in Eqs. (22–24). Briefly, the axis of the linker-drug complex has been specified as the line connect‐
ing the two most distant non-hydrogen (NH) atoms of the linker-drug complex. S7b. Calculate the axis of the selected
engineered cysteine as specified in Eqs. (25–27). Briefly, the axis of the cysteine residue has been specified as the line
connecting the alpha carbon (Cα) atom and the sulfur (S) atom of the cysteine side chain. S7c. Find the atoms that will
determine the distance between the linker-drug complex and the cysteine residue, as specified in Eqs. (33–35). Briefly,
the distance between the linker-drug complex and the cysteine has been specified as the distance between the atoms
participating in the disulfide bond between the two molecules. S8. Reconfigure the linker-drug complex. S8a. Get the
atomic coordinates of the linker-drug complex from its PDB HETATM records (linkerdrug.pdb). S8b. Rotate the linker-
drug complex using the affine transformation (Eqs. (1–15)). Apply the affine transformation to the linker-drug complex
for a = 1, Tx = Ty = Tz and the values of the variables rx, ry, rz in [−180°, +180°] that satisfy a specific condition, as defined
in Eq. (29). Briefly, the condition is the minimization of the absolute value of the angle between the axes of the linker-
drug complex and the cysteine residue. S8c. Update (optional) the PDB records of the linker-drug complex with the
modified coordinates (from step S8b). S8d. Translate the linker-drug complex using the affine transformation (Eqs. (1–
15)). Apply the affine transformation to the linker-drug complex for a = 1, rx = ry = rz = 0, and the values of the variables
Tx, Ty, Tz that satisfy a specific condition, as defined in Eq. (37). Briefly, the condition is the minimization of the abso‐
lute value of the difference between the distance of the two molecules and the official length of the disulfide bond. S8e.
Update the PDB records of the linker-drug complex with the modified coordinates. S8f. Save the updated PDB records
of the linker-drug complex in a new PDB file (e.g., linkerdrug_rt.pdb). S9. Merge the PDB files of the THIOMAB and
the reconfigured linker-drug complex to produce the PDB file of the THIOMAB-drug conjugate. S9a. Renumber the
PDB records of the linker-drug complex (from step S8), since they will be placed after the antibody records in step S9c.
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S9b. Form computationally a disulfide bond between the cysteine and the linker-drug complex, by updating the PDB
CONECT records of the antibody and linker. S9c. Save the necessary data to a new file that will represent the final
THIOMAB-drug conjugate (e.g., tdc.pdb). Those data include (i) the PDB ATOM and HETATM records of the anti‐
body (thiomab.pdb) (from step S2); (ii) the renumbered PDB HETATM records of the reconfigured linker-drug com‐
plex (from step S9a); (iii) the updated PDB CONECT records of the antibody and the linker-drug complex, including
the one that contains the disulfide bond (from steps S9a, S9b).
Once the input files of the engineered antibody, linker, and drug are available, the necessary
PDB records are loaded into instances of suitable data structures (step S3). The remaining
process can be divided in two basic stages, which are the synthesis of a linker-drug complex
molecule from the linker and drug (steps S4–S6), and the synthesis of an antibody-drug
conjugate from the linker-drug complex and engineered antibody (steps S7–S9). More
specifically, while the linker remains fixed, the drug undergoes rotation and translation,
brought in a specific position near the linker (step S5). Following that, the two molecules are
linked through a hydrogen bond, and their PDB files are combined to form a linker-drug
complex (step S6). While the antibody remains fixed, the linker-drug complex undergoes
rotation and translation (step S8). The two molecules are linked through a disulfide bond and
their PDB files are combined to produce the final THIOMAB-drug conjugate (step S9). Since
a drug molecule can contain more than one pair of atoms that can form a hydrogen bond with
the linker, it is possible to either select the drug conjugation site, or produce more than one
final TDCs. The computational method proposed in this chapter is described more analytically
with the following steps (S1–S9), depicted in Figure 2.
2.2. Affine transformation
The modification of atomic coordinates serves the purpose of altering the relative positions
between the different molecules. However, it should not disrupt the initial lines and distances
between the atoms of a single molecule, since that would interfere with the validity of its
chemical structure. To that end, an affine transformation was employed for the reconfiguration
of a molecule [42–45]. According to [45], the transformation of a rigid body in three-dimen‐
sional space can be described with the following equations:
00 01 02 03x R * x R * y R * z R¢ = + + + (1)
10 11 12 13* * *+¢ = + +y R x R y R z R (2)
20 21 22 23* * *+¢ = + +z R x R y R z R (3)
00 *cos *cos= z yR a r r (4)
( )01 * cos *sin *sin sin *cos= -z y x z xR a r r r r r (5)
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( )02 * cos *sin *cos sin *sin= +z y x z xR a r r r r r (6)
03 = xR T (7)
10 *sin *cos= z yR a r r (8)
( )11 * sin *sin *sin cos *cos= +z y x z xR a r r r r r (9)
( )12 * sin *sin *cos cos *cos= -z y x z xR a r r r r r (10)
13 = yR T (11)
20 *sin= - yR a r (12)
21 *cos *sin= y xR a r r (13)
22 *cos *cos= y xR a r r (14)
23 = zR T (15)
where x, y, z are the initial coordinates of a point of the rigid body, x′, y′, z′ are the coordinates
of the same point after the application of the transformation, α is the scaling factor, rx, ry, rz are
the rotation angles of the body around the x, y, z axis, respectively, and Tx, Ty, Tz are the
distances according to which each point will be translated in the x, y, z direction, respectively.
From Eqs. (1–15), we can deduce that if we apply the values a = 1, rx = ry = rz = Tx = Ty = Tz = 0,
it will be x′ = x, y′ = y, z′ = z.
The term point used above refers not to a set of constant coordinates but to an element of the
body with variable coordinates. In the context of molecular reconfiguration, each molecule
was considered as a rigid body. Each atom of a molecule was seen as a single point, since an
atom is assigned one set of three-dimensional Cartesian coordinates according to the PDB
format. The Cartesian coordinates of an atom of a molecule correspond to the variables x,y,z,
x′,y′,z′ of Eqs. (1–15). The scaling factor α was always set to the value of 1, because scaling the
molecules would result in the disruption of their structure.
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2.3. Rotation
According to the method presented in this chapter, in order to perform the rotation of a
molecule A in reference to a fixed molecule B, the affine transformation is applied to A without
using the translation and scaling functions, for the parameter values a = 1, Tx = Ty = Tz = 0. The
values of rx, ry, rz that satisfy a certain condition (defined in Eqs. (28, 29)) are searched for in
the interval [−180°, +180°]. Finally, the affine transformation is applied to molecule A for the
found rx, ry, rz values. According to Figure 2, rotation occurs in two occasions in our method.
First, the drug adopts the role of molecule A and the linker adopts the role of molecule B (step
S5b). Later, the linker-drug complex adopts the role of molecule A and the cysteine takes the
role of B (step S8b).
2.4. Translation
According to the method presented in this chapter, in order to perform the translation of a
molecule A in reference to a fixed molecule B, the affine transformation is applied to A without
using the rotation and scaling functions, for the parameter values a = 1, rx = ry = rz = 0. The values
of Tx, Ty, Tz that satisfy a certain condition (Eqs. (36, 37)), are searched in the interval [−D, +D].
Usually, the value D = 200 was sufficient to complete the search successfully; otherwise, a larger
D value was applied. Finally, the affine transformation is applied to molecule A for the found
Tx, Ty, Tz values. According to Figure 2, translation occurs in two occasions in our method.
First, the drug adopts the role of the molecule A undergoing translation, and the linker adopts
the role of the fixed molecule B (step S5d). Later, the linker-drug complex adopts the role of
the molecule A undergoing translation, and the cysteine adopts the role of the fixed molecule
B (step S8d).
2.5. Axes
As mentioned in Section 2.3, the rotation of a molecule A (i.e., the drug or linker-drug complex)
in relation to its corresponding fixed molecule B (i.e., the linker or antibody, respectively) is
performed for a = 1, Tx = Ty = Tz = 0 and the values of the variables rx, ry, rz that satisfy a certain
condition. That condition is the minimization of the absolute value of the angle between the
axes of the two molecules (Eqs. (28, 29)).
In the context of this project, the axis of each molecule has been defined by taking into account
the desired final layout of the three molecules. In the lysine [34] and cysteine conjugation
methods, the same kind of bond connects the linker with the drug. Therefore, in both cases,
the drug axis is defined by the drug atoms participating in the hydrogen bond with the linker,
which are a hydrogen (H) atom and the electronegative (EN) atom covalently bonded to it
[Eqs. (16–18); Figure 2, step S4a]. The linker axis has been specified so as to connect the two
most distant non-hydrogen linker atoms because that line is quite representative of the linker
shape [Eqs. (19–21); Figure 2, step S4b]. Given the chemical structure C12S of the linker used
in cysteine conjugation, those two atoms are always the sulfur (S) atom and its most distant
carbon (C) atom. On a similar note, the axis of the linker-drug complex connects the two most
distant non-hydrogen atoms of the linker-drug complex [Eqs. (22–24); Figure 2, step S7a]. The
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cysteine axis has been defined as the line going through the alpha carbon (Cα) and sulfur atoms
(S) of the cysteine side chain [Eqs. (25–27); Figure 2, step S7b]. This line was chosen for its
direction towards the exterior of the antibody, which is the desired direction for the linker-
drug complex. In the lysine conjugation of [34], the linker C15N was used, therefore the linker
axis was defined by the nitrogen (N) atom with its most distant carbon (C) atom. Also, the
lysine axis went through the alpha carbon (Cα) and nitrogen (N) atoms of the lysine side chain.
( ) ( )1      , , , , = =d Hd Hd HdH atom of drugp x y z x y z (16)
( ) ( )2      , , , , = =d ENd ENd ENdEN atom of drugp x y z x y z (17)
( ) ( ) ( )
( )
1 1 2:  , , *    , , 
* , ,  ,  
= + - = +
- - - -¥ < < +¥
d d d d d Hd Hd Hd
d Hd ENd Hd ENd Hd ENd d
L x y z p t p p x y z
t x x y y z z t (18)
( ) ( )1      , , , , = =l NHl NHl NHlNH atom of linkerp x y z x y z (19)
( ) ( )2      , , , , = =l Sl Sl SlS atom of linkerp x y z x y z (20)
( ) ( ) ( )
( )
1 1 2:  , , *    , , 
* , ,  , 
= + - = +
- - - -¥ < < +¥
l l l l l NHl NHl NHl
l NHl Sl NHl Sl NHl Sl l
L x y z p t p p x y z
t x x y y z z t (21)
( ) ( )1      , , , , -= =ld NHld NHld NHldNH atom of linker drugp x y z x y z (22)
( ) ( )2      , , , , -= =ld Sld Sld SldS atom of linker drugp x y z x y z (23)
( ) ( ) ( )
( )
1 1 2:  , , *    , , 
* , ,    , 
= + - = +
- - - -¥ < < +¥
ld ld ld ld ld NHld NHld NHld
l NHld Sld NHld Sld NHld Sld ld
L x y z p t p p x y z
t x x y y z z t (24)
( ) ( )1      , , , , = =cys Sc Sc ScS atom of Cysteinep x y z x y z (25)
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( ) ( )2      , , , , = =cys Cc Cc CcCa atom of Cysteinep x y z x y z (26)
( ) ( ) ( )
( )
1 1 2:  , , *    , , 
* , ,  , 
= + - = +
- - - -¥ < < +¥
cys cys cys cys cys Sc Sc Sc
cys Sc Cc Sc Cc Sc Cc cys
L x y z p t p p x y z
t x x y y z z t (27)
( ), , : ,  0Ð = °x y z d lr r r L L (28)
( ), , : ,  0Ð = °x y z ld cysr r r L L      (29)
2.6. Distances
As mentioned in Section 2.4, the translation of a molecule A (i.e., the drug or the linker-drug
complex) in relation to its corresponding fixed molecule B (i.e., the linker or the antibody,
respectively) is performed for a = 1, rx = ry rz = 0, and the values of the variables Tx, Ty, Tz that
satisfy a certain condition. That condition is the minimization of the absolute value of the
difference between the distance of the two molecules and a fixed value l (Eqs. (36, 37)). The
definitions of the distance between two molecules and the fixed value are given below.
Taking into consideration the desired connectivity between the three molecules, in the context
of this project, the distance between two molecules was defined as the distance between the
atoms that will participate in the intended intermolecular bond (hydrogen or disulfide bond,
Figure 1). As a consequence, the fixed value l was defined as the official length of that
intermolecular bond (lHb = 1.5–2.5 Å for the Hydrogen bond, lSSb = 2.05 Å for the disulfide bond).
In more detail, in both lysine and cysteine conjugation, the distance between the drug and
linker was defined by the drug hydrogen (H) atom and the linker electronegative (EN) atom
participating in the H bond between the linker and drug [Eqs. (30–32); Figure 2, step S4c]. In
regard to the distance between the linker-drug complex and the conjugation residue, in lysine
conjugation, it was defined by the linker nitrogen (N) atom and the lysine hydrogen (H) atom
bonded to the side chain nitrogen atom. In cysteine conjugation, however, it has been defined
as the distance between the sulfur (S) linker atom and the sulfur atom of the cysteine side chain
[Eqs. (33–35); Figure 2, step S7c]. The translation of the drug in relation to the linker is
performed for the values of the variables Tx, Ty, Tz for which the distance between the two
molecules takes the official length lHb = 1.5–2.5 Å of the hydrogen bond (Eq. (36)). The transla‐
tion of the linker-drug complex in relation to the cysteine is performed for the values of the
variables Tx, Ty, Tz for which the distance between the two molecules takes the official length
lSSb = 2.05 Å of the disulfide bond (Eq. (37)):
( ) ( ) 1     , , , , = = =d Hd Hd Hd dH atom of drugp x y z x y z p (30)
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( ) ( ) ( )1      , , , ,  , , = = =l ENl ENl ENl Cl Cl ClEN atom of linkerp x y z x y z x y z (31)
1 - = -d l d lD p p    (32)
( ) ( )2      , , , , = =l Sl Sl SlS atom of linkerp x y z x y z (33)
( ) ( )     , , , , = =cys Scys Scys ScysS atom of Cysteinep x y z x y z (34)
2 - = -cys l cys lD p p    (35)
, , : 0- - =x y z d l HbT T T D l (36)
, , : 0- - =x y z cys l SSbT T T D l      (37)
where the variables Tx, Ty, Tz of Eq. (36) refer to the translation of the drug (Figure 2, step S5d),
while the variables of Tx′, Ty′, Tz′ Eq. (37) refer to the translation of the linker-drug complex
(Figure 2, step S8d).
2.7. Implementation
The steps S1 and S2 (see the Figure 2) that involve the selection and preparation of the input
files of the engineered antibody, the linker, the drug, as well as the selection of the conjugation
cysteine residue, are carried out manually. The steps S3–S9 have been developed as a C++
program, and therefore can be executed automatically. In order to make the necessary data
management, a number of classes and functions were created in regard to the PDB records
used, the three-dimensional points and lines, as well as the affine transformation.
3. Results
The method described in the previous section has been applied to various antibody and drug
combinations, taking about 10–13 seconds for each TDC to be generated. In Figure 3, the basic
stages of the production of a THIOMAB-drug conjugate are depicted. First, the drug and linker
are formed in two independent PDB files. The axis of each molecule is depicted as a white line,
and the initial angle between them is 98.2° (Figure 3a). The drug is rotated, and the angle
between the two axes becomes 0.08° (Figure 3b). The initial distance between the atoms that
will form the hydrogen bond (the C atom of the linker and the H atom of the drug, bonded
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covalently to an O drug atom) is 28.02 Å. The drug is translated and the distance between the
two atoms becomes 1.51 Å (Figure 3c). The linker has remained fixed. The two molecules are
merged into a linker-drug complex, whose new axis is depicted as a white line (Figure 3d).
The residue valine of the antibody with PDB id 4GAG, with sequence number 206 on the light
chain (LC-VAL206), is replaced by a cysteine, whose axis is calculated (Figure 3e). The initial
angle between the axis of the linker-drug complex and the axis of the cysteine is 105.6°, and
the distance between the sulfur atoms of the cysteine and the linker is 54.75 Å. The linker-drug
complex is rotated and translated, so that the angle becomes 0.083° and the distance becomes
2.07 Å. Finally, the linker-drug complex is connected with the cysteine (Figure 3f).
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Figure 3. The basic stages of the computational production of a TDC. (a) Left: The linker molecule C12S. Right: The
drug with NCI sequence number 9, before its reconfiguration. Angle between the two axes: 98.2°. (b) The linker and
the rotated drug. Angle between the two axes: 0.08°. Distance between the H atom of the drug and the C atom of the
linker: 28.02 Å. (c) The linker and the translated drug. Distance between the H atom of the drug and the C atom of the
linker: 1.51 Å. (d) The linker-drug complex. (e) The engineered cysteine that has replaced the residue LC-VAL206 on
the antibody with PDB id 4GAG. Initial angle between the axes of the cysteine and the linker-drug complex: 105.6°.
Initial distance between the two S atoms: 54.75 Å. (f) The linker-drug complex conjugated to the engineered cysteine.
Angle between the axes of the cysteine and the linker-drug complex: 0.084°. Distance between the two S atoms: 2.07 Å.
More examples of produced TDCs are demonstrated in Figure 4. The TDC composed by the
antibody with PDB id 4GAJ, the linker molecule C12S and the drug with sequence number 5
(nci_5.pdb) is depicted in Figure 4(a). A hydrogen bond connects the drug with the linker, and
a disulfide bond connects the engineered cysteine on the antibody with the linker-drug
complex. The cysteine has replaced the solvent-accessible amino acid alanine with residue
sequence number 114, at the heavy chain of the antibody (HC-ALA114). The same TDC is
depicted from a closer distance at the right of the figure. In Figure 4b, a similar TDC composed
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by the antibody with PDB id 4GAJ, the linker molecule C12S and the drug with sequence
number 7 (nci_7.pdb) is depicted. The above technique can be used for the conjugation of TDCs
with more than one drug molecules per antibody. Figure 4c depicts a TDC with a DAR of 2,
composed by the antibody with PDB id 4GAG, to which two drug molecules with sequence
number 1 (nci_1.pdb) have been conjugated. The engineered cysteines that serve as conjuga‐
tion sites have replaced the solvent-accessible residues alanine with sequence number 114 at
the heavy chain and valine with sequence number 206 at the light chain (LC-VAL206). The
conjugation areas of the same TDC are demonstrated from a closer distance at the right of the
figure. The linker and the drugs used in the examples are depicted in Figure 5.
Figure 4. (a) Left: TDC composed by the antibody with PDB id 4GAJ, the linker molecule C12S, and the drug with se‐
quence number 5. The drug has been conjugated through the linker to the engineered cysteine that has replaced the
residue HC-ALA114. Right: The same TDC from a closer distance. (b) Left: TDC composed by the antibody with PDB
id 4GAJ, the linker molecule C12S, and the drug with sequence number 7. The drug has been conjugated through the
linker to the engineered cysteine that has replaced the residue HC-ALA114. Right: The same TDC from a closer dis‐
tance. (c) Left: TDC composed by the antibody with PDB id 4GAG, two linker molecules C12S, and two drug molecules
with sequence number 1. The antibody conjugation sites are engineered cysteines that have replaced the residues HC-
ALA114, and LC-VAL206. Right: The same TDC from a closer distance.
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Figure 5. (a) The linker molecule C12S. (b) The cytotoxic drugs used in Figures 3 and 4. Top left: the drug with sequence
number 1 (nci_1.pdb). Top right: the drug with sequence number 5 (nci_5.pdb). Bottom left: the drug with sequence
number 7 (nci_7.pdb). Bottom right: the drug with sequence number 9 (nci_9.pdb).
4. Discussion
This chapter has presented a computational method for site-specific formulation of ADCs, by
conjugating the cytotoxin and the linker to engineered cysteines on the surface of the antibody.
A hydrogen bond is employed to connect the linker with the drug, forming a linker-drug
conjugate, which is then attached through a disulfide bond to the selected engineered cysteine.
The change of the atomic coordinates of a molecule was implemented with an affine transfor‐
mation. The generation of the linker molecule C12S, as well as the cysteine replacement, was
achieved through molecular modeling software [36, 42].
The present chapter proposes a general way to implement computationally ADC molecules
using data from established databases. The common antibodies used do not target cancer-
specific molecules, as opposed to antibodies that are parts of real ADCs. The employment of
antibodies with cancer-specific antigens was not feasible, since their three-dimensional
structures are not available. However, considering that the conjugation occurs in the preserved
regions of the antibody, the same techniques could be applied using the PDB file of any full
antibody. In addition, conventional anticancer drugs were used, since the three-dimensional
structures of the more potent drugs used in ADCs currently are not available. It is important
to note that the results of the presented method are not proposed as real anticancer drugs. The
presented method is an attempt to simulate ADCs using programming techniques and
available data.
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Site-specific conjugation is a substantial goal in ADC development, since it gives the ability to
control the pharmacokinetic and therapeutic properties of the produced ADCs. Aside from
the replacement of residues with cysteines, mentioned in Section 1, a similar concept is the
substitution of cysteines with serines in order to reduce the number of inter-chain cysteines
available for conjugation. Another technique is the introduction of non-native amino acids in
the antibody sequence, such as selenocysteine, acetylphenylalanine, para-acetylphenylala‐
nine, and para-azidophenylalanine, utilizing their ability to provide orthogonal conjugation
chemistries that are not available from original residues. Enzymes have been used to help form
bonds between the antibody, the linker and drug, a method called enzymatic conjugation. An
additional strategy is the conjugation at the glycosylation sites of the antibody, leaving the
amino acid sequence of the antibody and the cell culture condition intact. For example, sialic
acid moieties can be introduced enzymatically to the antibody, which can then be oxidized to
introduce aldehyde groups. The resulting antibodies can then form stable oxime bonds with
drugs containing aldehyde-reactive aminooxy groups [22, 46–59].
A number of actions could be taken to improve and expand the work described in this chapter.
Some of our future goals is the implementation of more site-specific conjugation ways, the use
of antibody forms alternative to the full monoclonal antibody, such as scFvs, diabodies, and
minibodies, as well as other non-cleavable and cleavable linker molecules. In addition, the
automatic recognition of all amino acids available for conjugation given a specific antibody
would be interesting, as well as the estimation of the best drugs and linkers given a conjugation
method. Finally, the conditions and equations used could be modified in order to take into
consideration other factors.
Acknowledgements
Funding was received through an IKY Fellowship of Excellence for postgraduate studies in
Greece—Siemens Program. The authors confirm that the funder had no influence over the
study design, content of the chapter, or selection of this book.
Author details
Arianna Filntisi1,2*, Dimitrios Vlachakis2 and George K. Matsopoulos1
*Address all correspondence to: arianna.filntisi@gmail.com
1 School of Electrical and Computer Engineering, National Technical University of Athens,
Athens, Greece
2 Computational Biology and Medicine Group, Biomedical Research Foundation of the
Academy of Athens, Athens, Greece
A Bioinformatics Method for the Production of Antibody-Drug Conjugates Through Site-Specific Cysteine Conjugation
http://dx.doi.org/10.5772/62747
47
References
[1] National Cancer Institute at the National Institutes of Health. 2014. Available from:
http://www.cancer.gov/ [Accessed: 2014–03]
[2] American Cancer Society. 2014. Available from: http://www.cancer.org/ [Accessed:
2014–03]
[3] Cancer Research Institute. 2014. Available from: http://www.cancerresearch.org/
[Accessed: 2014–02]
[4] Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, et al. A review on various
targeted anticancer therapies. Target Oncology. 2012;7(1):69–85. DOI: 10.1007/
s11523-012-0212-2
[5] Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin
North Am.2012;26(3):447–481. DOI: 10.1016/j.hoc.2012.02.013
[6] Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and
challenges. Pharmacol Ther. 2013;138(3):452–469. DOI: 10.1016/j.pharmthera.
2013.03.004
[7] Goldmacher VS, Chittenden T, Chari RVJ, Kovtun YV, Lambert JM. Antibody-drug
conjugates for targeted cancer therapy. In: Desai MC, editor. Annual Reports in
Medicinal Chemistry, Volume 47. Academic Press; 2012. p. 349–366.
[8] Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future
perspectives. J Control Release. 2012;161(2):422–428. DOI: 10.1016/j.jconrel.2012.01.026
[9] Kovtun Y V, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett.
2007;255(2):232–240. DOI: http://dx.doi.org/10.1016/j.canlet.2007.04.010
[10] Gerber H-P, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor
vasculature: Current and future developments. MAbs. 2009;1(3):247–253. DOI: 10.4161/
mabs.1.3.8515
[11] Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconju‐
gates. Biotechnol. 2005;23(9):1137–1146. DOI: 10.1038/nbt1141
[12] Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al.
Antibody-drug conjugates: current status and future directions. Drug Discov Today.
2014;19(7):869–881. DOI: 10.1016/j.drudis.2013.11.004
[13] Alley SC, Anderson KE. Analytical and bioanalytical technologies for characterizing
antibody-drug conjugates. Curr Opin Chem Biol. 2013;17(3):406–411. DOI: 10.1016/
j.cbpa.2013.03.022
[14] Iyer U, Kadambi VJ. Antibody drug conjugates-Trojan horses in the war on cancer. J
Pharmacol Toxicol Methods. 2011;64(3):207–212. DOI: 10.1016/j.vascn.2011.07.005.
Bioinformatics - Updated Features and Applications48
[15] Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6(5):343–
357. DOI: 10.1038/nri1837
[16] Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered
thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human
epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16(19):
4769–4778. DOI: 10.1158/1078-0432.CCR-10-0987
[17] Dere R, Yi J-H, Lei C, Saad OM, Huang C, Li Y, et al. PK assays for antibody-drug
conjugates: case study with ado-trastuzumab emtansine. Bioanalysis. 2013;5(9):1025–
1040. DOI: 10.4155/bio.13.72
[18] Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of
drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin
Cancer Res. 2004;10(20):7063–7070. DOI: 10.1158/1078-0432.CCR-04-0789
[19] Flemming A. Antibody engineering: fine-tuning antibody-drug conjugates. Nat Rev
Drug Discov. 2014;13(3):178. DOI: 10.1038/nrd4266
[20] Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, et al. A general approach to
sitespecific antibody drug conjugates. Proc Natl Acad Sci U S A. 2014;111(5):1766–1771.
DOI: 10.1073/pnas.1321237111
[21] Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conju‐
gation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotech‐
nol. 2008;26(8):925–932. DOI: 10.1038/nbt.1480
[22] Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol.
2009;13(3):235–244. DOI: 10.1016/j.cbpa.2009.03.023
[23] Lyon RP, Meyer DL, Setter JR, Senter PD. Conjugation of anticancer drugs through
endogenous monoclonal antibody cysteine residues. Methods Enzymol. 2012;502:123–
138. DOI: 0.1016/B978-0-12-416039-2.00006-9
[24] Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, Vandlen R, et al. Rapid identi‐
fication of reactive cysteine residues for site-specific labeling of antibody-Fabs. J
Immunol Methods. 2008;332(1–2):41–52. DOI: 10.1016/j.jim.2007.12.011
[25] Li X, Patterson JT, Sarkar M, Pedzisa L, Kodadek T, Roush WR, et al. Site-specific dual
antibody conjugation via engineered cysteine and selenocysteine residues. Bioconjug
Chem. 2015;26(11):2243–2248. DOI: 10.1021/acs.bioconjchem.5b00244
[26] Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates
the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotech‐
nol. 2012;30(2):184–189. DOI: 10.1038/nbt.2108
[27] Strop P, Liu S-H, Dorywalska M, Delaria K, Dushin RG, Tran T-T, et al. Location
matters: site of conjugation modulates stability and pharmacokinetics of antibody drug
conjugates. Chem Biol. 2013;20(2):161–167. DOI: 10.1016/j.chembiol.2013.01.010
A Bioinformatics Method for the Production of Antibody-Drug Conjugates Through Site-Specific Cysteine Conjugation
http://dx.doi.org/10.5772/62747
49
[28] Boylan NJ, Zhou W, Proos RJ, Tolbert TJ, Wolfe JL, Laurence JS. Conjugation site
heterogeneity causes variable electrostatic properties in Fc conjugates. Bioconjug
Chem. 2013;24(6):1008–1016. DOI: 10.1021/bc4000564
[29] Worldwide PDB (wwPDB) organization. 2003 [Updated: 2016]. Available from: http://
www.wwpdb.org/ [Accessed: 2015]
[30] RCSB Protein Data Bank. 2000 [Updated: 2016]. Available from: http://www.rcsb.org
[Accessed: 2016]
[31] Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN,
Bourne PE. The Protein Data Bank. Nucl. Acids Res. 2000;28(1):235–242. DOI: 10.1093/
nar/28.1.235
[32] Chemical Computing Group Inc. Molecular Operating Environment (MOE). 2013.
[Accessed: 2014]
[33] Filntisi A, Papangelopoulos N, Bencurova E, Kasampalidis I, Matsopoulos G, Vlachakis
D, et al. State-of-the-Art Neural Networks Applications in Biology. Int J Syst Biol
Biomed Technol. 2013;2(4):63–85. DOI: 10.4018/ijsbbt.2013100105
[34] Filntisi A, Vlachakis D, Matsopoulos G, Kossida S. 3D structural bioinformatics of
proteins and antibodies: state of the art perspectives and challenges. Int J Syst Biol
Biomed Technol. 2013;2(3):67–74. DOI: 10.4018/ijsbbt.2013070105
[35] Vlachakis D, Tsagrasoulis D, Megalooikonomou V, Kossida S. Introducing Drugster: a
comprehensive and fully integrated drug design, lead and structure optimization
toolkit. Bioinformatics. 2013;29(1):126–128. DOI: DOI: 10.1093/bioinformatics/bts637
[36] Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF
Chimera-a visualization system for exploratory research and analysis. J Comput Chem.
2004;25(13):1605–1612. DOI: 10.1002/jcc.20084
[37] Toshimoto K, Wakayama N, Kusama M, Maeda K, Sugiyama Y, Akiyama Y. In silico
prediction of major drug clearance pathways by support vector machines with feature
selected descriptors. Drug Metab Dispos. 2014;42(11):1811–1819. DOI: 10.1124/dmd.
114.057893
[38] Mitra A, Kesisoglou F, Dogterom P. Application of absorption modeling to predict
bioequivalence outcome of two batches of etoricoxib tablets. AAPS PharmSciTech.
2015;16(1):76–84. DOI: 10.1208/s12249-014-0194-8
[39] Vlachakis D, Kossida S. Antibody drug conjugate bioinformatics: drug delivery
through the letterbox. Comput Math Methods Med. 2013;2013(2013):282398.
DOI:http://dx.doi.org/10.1155/2013/282398
[40] Scilligence. JSDraw - Antibody-Drug Conjugate [Internet]. 2014 [Updated: 2015].
Available from: http://www.elncloud.com/jsdrawapp/jsdraw/ADC.htm [Accessed:
2016]
Bioinformatics - Updated Features and Applications50
[41] Sukumaran S, Gadkar K, Zhang C, Bhakta S, Liu L, Xu K, et al. Mechanism-based
pharmacokinetic/pharmacodynamic model for THIOMABTM drug conjugates. Pharm
Res. 2015;32(6):1884–1893. DOI: 10.1007/s11095-014-1582-1
[42] Filntisi A, Vlachakis D, Matsopoulos GK, Kossida S. Computational construction of
antibody-drug conjugates using surface lysines as the antibody conjugation site and a
non-cleavable linker. Cancer Inform. 2014;13:179–186. DOI: 10.4137/CIN.S19222
[43] Wolfram Mathworld. http://mathworld.wolfram.com/AffineTransformation.html
[Internet]. 1999 [Updated: 2006]. Available from: http://mathworld.wolfram.com/
AffineTransformation.html [Accessed: 2014]
[44] Michigan Technical University. Geometric Transformations [Internet]. 1998 [Updated:
2011]. Available from: http://www.cs.mtu.edu/~shene/COURSES/cs3621/NOTES/
geometry/geo-tran.html [Accessed: 2015]
[45] Steven M. Lavalle, Cambridge University Press. Planning Algorithms [Internet]. 2006
[Updated: 2012]. Available from: http://planning.cs.uiuc.edu/node104.html [Accessed:
2015]
[46] Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug
conjugates for cancer therapy. MAbs. 2014;6(1):34–45. DOI: 10.4161/mabs.27022
[47] McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, et al. Engineered
antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
Protein Eng Des Sel. 2006;19(7):299–307. DOI: 10.1093/protein/gzl013
[48] Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical
characterization of antibody drug conjugates. MAbs. 2011;3(2):161–172. DOI: 10.4161/
mabs.3.2.14960
[49] Rabuka D, Rush JS, de Hart GW, Wu P, Bertozzi CR. Site-specific chemical protein
conjugation using genetically encoded aldehyde tags. Nat Protoc. 2012;7(6):1052–1067.
DOI: 0.1038/nprot.2012.045
[50] Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, et al. Site-specific
antibody-drug conjugation through glycoengineering. Bioconjug Chem. 2014;25(3):
510–520. DOI: 10.1021/bc400505q
[51] Zhu Z, Ramakrishnan B, Li J, Wang Y, Feng Y, Prabakaran P, et al. Site-specific
antibody-drug conjugation through an engineered glycotransferase and a chemically
reactive sugar. MAbs. 2014;6(5):1190–1200. DOI: 10.4161/mabs.29889
[52] Cai X, Janda KD. A chemoenzymatic approach toward the preparation of site-specific
antibody-drug conjugates. Tetrahedron Lett. 2015;56(23):3172–3175. DOI: 10.1016/
j.tetlet.2014.12.025
A Bioinformatics Method for the Production of Antibody-Drug Conjugates Through Site-Specific Cysteine Conjugation
http://dx.doi.org/10.5772/62747
51
[53] Kiick KL, Saxon E, Tirrell DA, Bertozzi CR. Incorporation of azides into recombinant
proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad
Sci U S A. 2002;99(1):19–24. DOI: 10.1073/pnas.012583299
[54] Hofer T, Skeffington LR, Chapman CM, Rader C. Molecularly defined antibody
conjugation through a selenocysteine interface. Biochemistry. 2009;48(50):12047–12057.
DOI: 10.1021/bi901744t
[55] Hofer T, Thomas JD, Burke TR, Rader C. An engineered selenocysteine defines a unique
class of antibody derivatives. Proc Natl Acad Sci U S A. 2008;105(34):12451–12456. DOI:
10.1073/pnas.0800800105
[56] Li X, Yang J, Rader C. Antibody conjugation via one and two C-terminal selenocys‐
teines. Methods. 2014;65(1):133–138. DOI: 10.1016/j.ymeth.2013.05.023
[57] Zimmerman ES, Heibeck TH, Gill A, Li X, Murray CJ, Madlansacay MR, et al. Produc‐
tion of site-specific antibody-drug conjugates using optimized non-natural amino acids
in a cell-free expression system. Bioconjug Chem. 2014;25(2):351–361. DOI: 10.1021/
bc400490z
[58] Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, et al. Synthesis of
site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad
Sci U S A. 2012;109(40):16101–16106. DOI: 10.1073/pnas.1211023109
[59] Sochaj AM, Świderska KW, Otlewski J. Current methods for the synthesis of homoge‐
neous antibody-drug conjugates. Biotechnol Adv. 2015;33(6):775–784. DOI: 10.1016/
j.biotechadv.2015.05.001
Bioinformatics - Updated Features and Applications52
